Cytek Biosciences, Inc. (CTKB) Financial Statements (2026 and earlier)

Company Profile

Business Address 47215 LAKEVIEW BOULEVARD
FREMONT, CA 94538
State of Incorp. DE
Fiscal Year End December 31
Industry (SIC) 3826 - Laboratory Analytical Instruments (benchmarking)
More info Complete Financial Analysis Financial Benchmarking

Balance Sheet (Statement of Financial Position) ($ in thousands)
Annual | Quarterly

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments90,85393,28175,47095,29998,716162,272
Cash and cash equivalent90,85393,28175,47095,29998,716162,272
Restricted cash and investments     2931
Receivables62,50956,63256,23255,02960,58852,634
Inventory, net of allowances, customer advances and progress billings48,42851,64949,48745,34743,89346,800
Inventory48,42851,64949,48745,34743,89346,800
Prepaid expense6,70710,25611,43411,74912,01710,530
Other current assets2,9772,9172,7622,2851,9432,341
Other undisclosed current assets180,522173,754187,440170,792179,260115,583
Total current assets:391,996388,489382,825380,501396,446390,191
Noncurrent Assets
Operating lease, right-of-use asset11,31511,15816,3879,86910,16810,124
Property, plant, and equipment, after accumulated depreciation, depletion, and amortization18,00918,04618,35217,83417,96218,508
Long-term investments and receivables  1,6001,6001,6001,6001,600
Long-term investments  1,6001,6001,6001,6001,600
Intangible asset, including goodwill, after accumulated amortization33,51834,37435,30836,10936,79136,675
Goodwill16,69716,69816,70716,67816,66316,183
Intangible asset, excluding goodwill, after accumulated amortization16,82117,67618,60119,43120,12820,492
Other noncurrent assets6,7044,4594,6834,5744,7594,950
Other undisclosed noncurrent assets  36,79334,16532,10931,77429,178
Total noncurrent assets:69,546106,430110,495102,095103,054101,035
TOTAL ASSETS:461,542494,919493,320482,596499,500491,226
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:23,41720,23321,60419,19721,44320,733
Accounts payable6,4107,6326,8536,2475,5295,389
Accrued liabilities23,41720,23321,60419,19721,44320,733
Other undisclosed accounts payable and accrued liabilities(6,410)(7,632)(6,853)(6,247)(5,529)(5,389)
Deferred revenue28,50428,73928,12827,70625,49225,365
Other liabilities16,97816,42614,71712,83613,4948,814
Other undisclosed current liabilities8,9059,8098,8217,9527,2347,885
Total current liabilities:77,80475,20773,27067,69167,66362,797
Noncurrent Liabilities
Liabilities, other than long-term debt41,47440,48641,70234,36435,05041,730
Deferred revenue18,33916,31516,62515,71716,09814,787
Estimated litigation liability6,7868,1588,4778,8199,03617,066
Other liabilities2,3072,5192,4812,3802,3642,121
Operating lease, liability14,04213,49414,1197,4487,5527,756
Other undisclosed noncurrent liabilities5256557919181,0501,236
Total noncurrent liabilities:41,99941,14142,49335,28236,10042,966
Total liabilities:119,803116,348115,763102,973103,763105,763
Equity
Equity, attributable to parent341,739378,571377,557379,623395,737385,463
Common stock129128127128129130
Additional paid in capital441,107435,284429,652426,705430,791430,072
Accumulated other comprehensive income (loss)2,241821(38)(609)16101
Accumulated deficit(101,738)(57,662)(52,184)(46,601)(35,199)(44,840)
Total equity:341,739378,571377,557379,623395,737385,463
TOTAL LIABILITIES AND EQUITY:461,542494,919493,320482,596499,500491,226

Income Statement (P&L) ($ in thousands)
Annual | Quarterly

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Revenues62,14152,29345,60241,45757,47651,500
Cost of revenue
(Cost of Product and Service Sold)		(29,256)(24,742)(21,735)(21,300)(23,824)(22,495)
Gross profit:32,88527,55123,86720,15733,65229,005
Operating expenses(38,479)(36,743)(34,491)(35,132)(30,666)(33,253)
Operating income (loss):(5,594)(9,192)(10,624)(14,975)2,986(4,248)
Nonoperating income1,5631,4233,8493,7097,3374,405
Investment income, nonoperating5805735555089131,433
Other nonoperating income2581,3443,7083,4924913,091
Interest and debt expense725(494)(414)(291)5,933(119)
Income (loss) from continuing operations before equity method investments, income taxes:(3,306)(8,263)(7,189)(11,557)16,25638
Other undisclosed income (loss) from continuing operations before income taxes (725)494414291(5,933)119
Income (loss) from continuing operations before income taxes:(4,031)(7,769)(6,775)(11,266)10,323157
Income tax expense (benefit)(40,045)2,2911,192(136)(680)784
Net income (loss):(44,076)(5,478)(5,583)(11,402)9,643941
Other undisclosed net income attributable to parent      
Net income (loss) available to common stockholders, diluted:(44,076)(5,478)(5,583)(11,402)9,643941

Comprehensive Income ($ in thousands)
Annual | Quarterly

3/31/2026
Q1
12/31/2025
Q4
9/30/2025
Q3
6/30/2025
Q2
3/31/2025
Q1
12/31/2024
Q4
9/30/2024
Q3
Net income (loss):(44,076)(5,478)(5,583)(11,402)9,643941
Comprehensive income (loss):(44,076)(5,478)(5,583)(11,402)9,643941
Other undisclosed comprehensive income (loss), net of tax, attributable to parent1,421859570(625)(86)296
Comprehensive income (loss), net of tax, attributable to parent:(42,655)(4,619)(5,013)(12,027)9,5571,237

Statements Sources

The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: